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Abstract 
Background: Haemoglobinuria is an uncommon complication of severe malaria, reflecting acute intravascular hae-
molysis and potentially leading to acute kidney injury. It can occur early in the course of infection as a consequence 
of a high parasite burden, or may occur following commencement of anti-malarial treatment. Treatment with quinine 
has been described as a risk factor; however the syndrome may also occur following treatment with intravenous 
artesunate. In Malaysia, Plasmodium knowlesi is the most common cause of severe malaria, often associated with high 
parasitaemia. Asplenic patients may be at additional increased risk of intravascular haemolysis.
Case presentation: A 61 years old asplenic man was admitted to a tertiary referral hospital in Sabah, Malaysia, with 
severe knowlesi malaria characterized by hyperparasitaemia (7.9 %), jaundice, respiratory distress, metabolic acidosis, 
and acute kidney injury. He was commenced on intravenous artesunate, but1 day later developed haemoglobinuria, 
associated with a 22 % reduction in admission haemoglobin. Additional investigations, including a cell-free hae-
moglobin of 10.2 × 105 ng/mL and an undetectable haptoglobin, confirmed intravascular haemolysis. The patient 
continued on intravenous artesunate for a total of 48 h prior to substitution with artemether–lumefantrine, and made 
a good recovery with resolution of his haemoglobinuria and improvement of his kidney function by day 3.
Conclusions: An asplenic patient with hyperparasitaemic severe knowlesi malaria developed haemoglobinuria after 
treatment with intravenous artesunate. There are plausible mechanisms for increased haemolysis with hyperparasi-
taemia, and following both splenectomy and artesunate. Although in this case the patient made a rapid recovery, 
knowlesi malaria patients with this unusual complication should be closely monitored for potential deterioration.
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Background
Haemoglobinuria reflects acute intravascular haemolysis, 
and can occur as a complication of severe malaria, poten-
tially leading to acute kidney injury. While it can occur 
early in the course of infection as a direct consequence 
of a high parasite burden and rupture of parasitized 
and unparasitized cells, it may also occur as a compli-
cation of anti-malarial treatment. In previous reports, 
haemoglobinuria occurring in patients with malaria has 
been referred to as blackwater fever. While definitions 
vary, the term was historically used to describe a clinical 
syndrome of haemoglobinuria, fever and jaundice that 
typically involved non- or partially immune European 
expatriates who had been residing in malaria-endemic 
areas and who had received, often intermittently, treat-
ment with quinine. More recent reports however, have 
described blackwater fever or haemoglobinuria in South-
east Asian adults [1] and in African children [2–5], 
including in those treated with artesunate [1, 6–8]. The 
syndrome is most commonly associated with falciparum 
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malaria, although has also been reported with Plasmo-
dium vivax [9] and with mixed species infections [1, 3], 
and in severe knowlesi malaria [10, 11].
The comparative risk of intravascular haemolysis in 
splenectomized patients with malaria has not been 
evaluated. Splenectomized patients are thought to be at 
increased risk of developing complications from malaria, 
and in patients with thalassaemia, asplenic patients expe-
rience more severe intravascular haemolysis [12]. Plas-
modium knowlesi is the most common cause of malaria in 
Malaysia and is associated with high parasitaemia infec-
tions [13]. In rhesus macaques with high parasitaemia P. 
knowlesi infections, haemoglobinuria was commonly a 
pre-terminal event [14, 15]. This report describes a case 
of haemoglobinuria that occurred in a splenectomized 
patient with severe knowlesi malaria, following treatment 
with intravenous artesunate.
Case presentation
A 61 years old farmer presented to Kudat District Hos-
pital in northeastern Sabah with a 3-day history of fever, 
rigours, cough, headache, arthralgia, and myalgia. He 
lived in a village near Kudat town and had recently trav-
elled to Banggi Island off the coast of Sabah, at the time 
highly endemic for malaria, where he had stayed over-
night in forested areas, and had seen monkeys. His past 
history was significant for having undergone a splenec-
tomy 5  years previously following a motor vehicle acci-
dent, hypertension, and self-reported malaria 10  years 
previously. His medications included life-long prophylac-
tic penicillin and perindopril. He denied having taken any 
anti-malarial medications prior to presentation.
On examination his temperature was 38.9  °C, heart 
rate 93 beats per minute, blood pressure 114/79  mm 
Hg, respiratory rate 36 breaths/minute and oxygen satu-
ration 88 % on room air. He was notably jaundiced and 
had a scar on his abdomen, but examination was oth-
erwise unremarkable. His urine was of normal colour. 
Blood film was reported as P. knowlesi, with a parasite 
count of 7.9  %. His haemoglobin was 15.2  g/dL, white 
cell count 8.7 × 103/μL, platelets 24 × 103/μL, and cre-
atinine 145  µmol/L (Table  1). He was commenced on 
intravenous artesunate in addition to ceftriaxone, and 
transferred to a tertiary referral hospital. An arterial 
blood gas taken the following morning on 35 % oxygen 
via a Venturi mask revealed metabolic acidosis with 
a pH of 7.31 and bicarbonate of 11  mmol/L. His chest 
X-ray was unremarkable. One day later, after two doses 
of intravenous artesunate given on admission and at 
12  h, he was noted to have “coca-cola” coloured urine 
(Fig. 1), with urinalysis positive for haemoglobin with no 
intact red blood cells. Additional blood investigations 
revealed a bilirubin of 181  µmol/L and elevated liver 
transaminases (Table 1). Glucose-6 phosphate dehydro-
genase (G6PD) activity was normal, thalassemia screen 
was negative, and dengue NS1 antigen was negative. 
Table 1 Laboratory values
a  Parasitaemia as reported by expert research microscopist. A total of 30 ring 
stage parasites, 35 trophozoites and 14 schizonts per 1000 RBCs were seen, 
accounting for a parasitaemia of 7.9 %, or 431,000 parasites/μL
Day 0 Day 1 Day 2 Day 3 Day 4
Parasite count 
(parasites/µL)
431,000a 56,000 14,880 Negative Negative
Haemoglobin 
(g/dL)
15.2 13.3 11.8 12.5 12.2
Haematocrit (%) 43.4 39.5 33.4 35.5 35.3
White blood cells 
(×103/µL)
8.7 10.9 10.7 11.5 11.9
Platelets (×103/µL) 24 28 29 52 104
Creatinine 
(µmol/L)


















Lactate (mmol/L) 1.89 1.74 1.30
Glucose (mmol/L) 8.0 12.1 10.8 9.3
Cell free haemo-
globin (ng/mL)




Fig. 1 Urine sample on day 1, after completion of two doses of 
intravenous artesunate
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Testing for leptospirosis was not performed. The patient 
received two further doses of artesunate (at 24 and 48 h) 
before changing to artemether–lumefantrine. He made 
a good clinical recovery, with improvement of his oxy-
gen saturation, jaundice, thrombocytopaenia, and renal 
function (creatinine 86  µmol/L on day 3; Table  1). By 
day 3 he was afebrile with no malaria parasites seen 
on blood film, and his haemoglobinuria had largely 
resolved. PCR confirmed P. knowlesi mono-infec-
tion. No pathogens were isolated from blood cultures 
taken after commencement of antibiotics. The patient 
received ceftriaxone for a total of 7 days.
As the patient was enrolled in a prospective pathophys-
iology study, venous blood was collected (14.5  h after 
commencement of intravenous artesunate) in lithium 
heparin and citrate tubes and centrifuged within 30 min, 
with plasma stored at −80 °C. Cell-free haemoglobin and 
haptoglobin were measured by enzyme-linked immuno-
sorbent assay (ELISA), revealing markedly elevated cell-
free haemoglobin (10.2 ×  105  ng/mL) and undetectable 
haptoglobin.
Discussion
This report describes a case of knowlesi malaria in a 
splenectomized patient, with WHO-defined criteria for 
severe disease, including hyperparasitaemia, respira-
tory distress, metabolic acidosis, and jaundice [16], who 
developed haemoglobinuria (sometimes referred to as 
blackwater fever) following treatment with artesunate. 
This is the second reported case of haemoglobinuria in a 
patient with severe knowlesi malaria treated with artesu-
nate [10], and, given the potential for association with 
acute kidney injury, highlights the importance of moni-
toring for this complication in such patients, particularly 
in those who are splenectomized.
The haemoglobinuria in this patient developed on the 
day following admission, and laboratory investigations, 
including a 22  % drop in haemoglobin, undetectable 
haptoglobin and massively elevated cell-free haemoglo-
bin, all confirmed intravascular haemolysis. The cause 
of this haemolysis is likely multifactorial. In the setting 
of hyperparasitaemia, rupture of parasitized red blood 
cells (RBCs) alone can be expected to cause substantial 
haemolysis; however the degree of anaemia in this case 
implies additional loss of unparasitized RBCs. In falcipa-
rum malaria, factors that may contribute to lysis of non-
parasitized RBCs include the direct effects of parasite 
products [17], inflammatory cytokines [18], complement 
activation [17, 19], and membrane lipid peroxidation 
[18]. However, in the current case the haemoglobinu-
ria occurred only after the patient received two doses of 
intravenous artesunate, and it is therefore possible that 
artesunate may have contributed to the haemolysis.
While haemoglobinuria is well documented as a com-
plication of quinine and other arylamino alcohol drugs, 
the link with artesunate is less well described. However, 
recent studies suggest that rates may be similar to those 
seen with quinine. In the AQUAMAT study involving 
African children with severe falciparum malaria, black-
water fever was reported in 18/2597 (0.7 %) patients fol-
lowing treatment with intravenous artesunate compared 
to 30/2591 (1.2 %) following treatment with intravenous 
quinine [6]. Blackwater fever was more common in the 
SEAQUAMAT study involving Southeast Asian adults 
and children with severe falciparum malaria, being 
reported in 49/730 (7 %) and 33/731 (5 %) following treat-
ment with artesunate and quinine, respectively [8]. In a 
smaller study, haemoglobinuria occurred in 3/76 (3.9 %) 
Ugandan children receiving intravenous artesunate for 
severe falciparum malaria [7].
In addition to these reports of haemoglobinuria occur-
ring following treatment with artesunate, there are 
numerous reports of artesunate-associated haemolytic 
anaemia occurring without haemoglobinuria [20–22]. 
Jaureguiberry et  al. described three patterns of haemo-
lytic anaemia occurring in patients with falciparum 
malaria treated with artesunate: (1) a ‘rising’ pattern, in 
which the nadir haemoglobin and peak of haemolysis 
occur before day 8; (2) a delayed pattern (post-artesunate 
delayed haemolysis; PADH), defined by a >10 % drop in 
haemoglobin or a >10  % rise in lactate dehydrogenase 
(LDH) occurring after day 8; and, (3) a ‘persistent pat-
tern’, in which anaemia and haemolysis occur before and 
after day 8 [22]. In a study of 60 non-transfused travellers 
with falciparum malaria treated with intravenous artesu-
nate, these patterns of post-artesunate haemolytic anae-
mia occurred in 32, 17 and 22 % of patients, respectively, 
with the rising pattern (as occurred in the current case) 
associated with a mean 21  % decline in haemoglobin 
and marked haemolysis until day 4 [22]. The association 
between these patterns of artesunate-associated haemo-
lytic anaemia and the occurrence of haemoglobinuria 
however remains uncertain.
The mechanisms of acute artesunate-related haemoly-
sis are unclear. One mechanism contributing to PADH is 
the splenic removal of parasites from RBCs, with these 
‘pitted’ once-infected RBCs then returned to the circu-
lation but with reduced lifespan [22]. This mechanism 
however is less likely to explain acute haemolysis. In 
addition, the degree of anaemia in this case, and in previ-
ous reports of PADH [23], suggests that artesunate may 
also contribute to haemolysis of non-parasitized RBCs. 
Artesunate contains a highly active endoperoxide bridge 
that, cleaved in the presence of haem, generates reactive 
oxygen species and other free radicals [24–27]; it is possi-
ble that this oxidative stress may contribute to haemolysis 
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of RBCs. Artesunate has also been shown to induce phos-
phatidylserine (PS) translocation at the RBC membrane 
[27]. PS is a membrane phospholipid which is normally 
located on the internal leaflet of the lipid bilayer, how-
ever may become exposed when cells undergo oxidative 
stress, or during parasite maturation [28, 29]. PS-RBCs 
have been shown to play a role in inflammation [30], 
coagulation [31], platelet activation [32], and adhesion to 
vascular endothelial cells [33], and may increase suscepti-
bility to haemolysis [12].
In this case, ceftriaxone was another possible cause of 
drug-induced haemolysis; haemolysis attributed to cef-
triaxone has been previously reported in a patient with 
severe falciparum malaria [34]. However, in the current 
case, the patient’s haemoglobinuria resolved despite 
continuation of ceftriaxone for a total of 7 days, making 
this unlikely. G6PD deficiency is a known risk factor for 
blackwater fever [1]; however, was not present in this 
case.
In the current case, the lack of a spleen likely contrib-
uted to the severity of intravascular haemolysis, and may 
have increased the risk of haemoglobinuria. In patients 
with haemoglobin E/β-thalassaemia disease, splenec-
tomy has been shown to be associated with increased 
intravascular haemolysis, possibly due to an absence of 
splenic filtering of aged and/or defective RBCs [12]. In 
addition, PS-RBCs have been shown to be increased in 
splenectomized individuals [30, 31]. Blackwater fever in 
a splenectomized patient with falciparum malaria has 
been reported [35]. However, whether risk of haemolysis 
is increased in splenectomized patients with malaria has 
not been evaluated.
This is the sixth report of knowlesi malaria to occur in 
a splenectomized patient. Previous reports include two 
cases of uncomplicated malaria [10] and three cases of 
severe malaria [10, 36, 37], one of which occurred in a 
patient with β-thalassaemia and was transfusion-acquired 
[37]. Of the four severe cases (including the current case), 
all had jaundice, respiratory distress and metabolic aci-
dosis, with two also complicated by acute kidney injury 
requiring dialysis [10, 36]. Not unexpectedly, in two cases 
parasite clearance was markedly delayed [10, 36]. In the 
two uncomplicated cases there was an absence of throm-
bocytopaenia [10], with this finding being notable due to 
the near-universal finding of thrombocytopaenia with 
knowlesi malaria in patients with intact spleens [10, 13]. 
An increase in platelet counts has also been reported in 
thalassaemic patients who are splenectomized; while the 
mechanisms are unclear, an increase in PS-RBCs may be 
contributory [12].
In this case, although stage 1 AKI [by Kidney Dis-
ease Improving Global Outcomes (KDIGO)] crite-
ria [38] was present on admission, the patient made a 
rapid recovery with anti-malarial treatment. In previous 
series, AKI has been a common complication of haemo-
globinuria/blackwater fever. In Vietnamese adults 42 % 
of cases had acute renal failure [1], while renal failure 
was seen in 16 % of Congolese children with blackwater 
fever [3]. In European expatriates, renal failure occurred 
in 70 % of cases with blackwater fever [39]. Haemoglo-
binuria has also been associated with AKI in other dis-
eases, including babesiosis [40], paroxysmal nocturnal 
haemoglobinuria [41–43], and post-cardiopulmonary 
bypass [44]. While the mechanisms of haemolysis-
induced AKI remain uncertain, direct tubular cell injury 
from free haem likely contributes [23, 45]. In addition, 
free haem has been shown to cause oxidative damage by 
lipid peroxidation, leading to renal injury through vaso-
constriction [46, 47]. Finally, cell-free haemoglobin is a 
scavenger of nitric oxide (NO) and in severe falciparum 
malaria has been shown to be associated with reduced 
NO-dependent endothelial function and impaired tis-
sue perfusion [48], possibly also contributing to renal 
injury.
Conclusions
This report describes a case of a splenectomized patient 
with severe knowlesi malaria who developed haemo-
globinuria following commencement of treatment with 
artesunate. The AKI in this case was not severe, ante-
dated the artesunate and the patient made a rapid recov-
ery despite continuation of artemisinins. Artesunate 
reduces mortality in severe falciparum malaria [6, 8] 
and is associated with lower case-fatality than quinine 
in severe knowlesi malaria [10, 11, 49], making it the 
clear treatment of choice for severe disease in knowlesi 
malaria [16]. Clinicians should however be aware of the 
possibility of this rare complication in knowlesi malaria 
with high parasitaemia so that patients can be adequately 
monitored for potential deterioration.
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